A 42-year-old man with advanced HIV/AIDS (CD4 count 45 cells/μL) presents with white plaques on his tongue and oral mucosa that cannot be scraped off easily. He also reports dysphagia and retrosternal chest pain. Endoscopy shows white plaques extending into the oesophagus. KOH mount of a biopsy specimen shows budding yeast and pseudohyphae. Culture grows white, creamy colonies on Sabouraud dextrose agar. The isolate produces germ tubes in human serum at 37°C and forms chlamydospores on cornmeal agar. What is the most appropriate first-line antifungal therapy for oesophageal candidiasis in this patient?

Explanation

## Treatment of Oesophageal Candidiasis in HIV/AIDS ### Clinical Context **Key Point:** Oesophageal candidiasis is an AIDS-defining illness (CD4 <50 cells/μL) and indicates severe immunosuppression. The organism is *Candida albicans* (confirmed by germ tube production and chlamydospore formation). ### Antifungal Therapy Comparison | Drug | Route | Dosing (Oesophageal) | Penetration | First-Line? | Notes | | --- | --- | --- | --- | --- | --- | | **Fluconazole** | IV/PO | 400 mg daily × 14–21 days | Excellent (GI tract) | **YES** | Azole; fungistatic; oral bioavailability ~90% | | **Amphotericin B lipid complex** | IV | 5 mg/kg/day × 14–21 days | Moderate | No | Fungicidal; reserved for refractory cases or severe disease | | **Caspofungin** | IV | 70 mg loading, then 50 mg daily | Moderate | No | Echinocandin; for azole-refractory disease | | **Itraconazole** | PO | 200 mg BD × 14–21 days | Variable (pH-dependent) | No | Older azole; less reliable absorption than fluconazole | ### Treatment Algorithm ```mermaid flowchart TD A["Oesophageal candidiasis in HIV/AIDS"]:::outcome --> B{"CD4 count <50?"}:::decision B -->|"Yes"| C{"Azole-naive or mild disease?"}:::decision B -->|"No"| D["Topical therapy (nystatin)"]:::action C -->|"Yes"| E["Fluconazole 400 mg daily × 14–21 days"]:::action C -->|"No or refractory"| F{"Severe/disseminated?"}:::decision F -->|"Yes"| G["Amphotericin B lipid complex"]:::action F -->|"Azole-resistant"| H["Caspofungin or Voriconazole"]:::action E --> I["Initiate/optimize ART"]:::action G --> I H --> I ``` ### Why Fluconazole is First-Line **High-Yield:** Fluconazole is the standard first-line agent for oesophageal candidiasis in HIV patients because: 1. **Excellent oesophageal penetration** — achieves high concentrations in the GI tract 2. **Oral bioavailability** — ~90% absorption, allowing seamless transition from IV to PO 3. **Efficacy** — 80–90% clinical response rate in non-refractory cases 4. **Safety profile** — well-tolerated; minimal drug interactions compared to itraconazole 5. **Cost-effectiveness** — significantly cheaper than echinocandins or amphotericin B **Clinical Pearl:** Fluconazole dosing for oesophageal candidiasis is **higher** (400 mg daily) than for oral thrush (100–200 mg daily) because oesophageal disease represents deeper tissue invasion. **Mnemonic:** **FLUC** — **F**luconazole is **L**ow-cost, **U**seful for GI penetration, and **C**ost-effective first-line. ### When to Switch Therapy **Warning:** If the patient fails to improve after 7–14 days of fluconazole, consider: - **Azole resistance** (rare in *C. albicans*, more common in *C. glabrata* or *C. auris*) - **Poor adherence** - **Inadequate CD4 recovery** (ART not optimized) - **Switch to:** Caspofungin or amphotericin B lipid complex ### Concurrent Management **Key Point:** Antifungal therapy alone is insufficient. The patient requires: - **Antiretroviral therapy (ART)** — essential to restore CD4 count >100 cells/μL - **Prophylaxis after treatment** — continue fluconazole 200 mg daily until CD4 >200 cells/μL for ≥3 months on ART [cite:Harrison's Principles of Internal Medicine 21e Ch 197; CDC HIV Treatment Guidelines 2023]